Ovid Therapeutics Secures $53.9M from Warrant Exercises, Issuing 38.5M Shares

summarizeSummary

Ovid Therapeutics announced the expiration and exercise of Series A Warrants, resulting in a $53.9 million cash infusion and the issuance of approximately 38.5 million new shares.

check_boxKey Events

• Warrant Expiration and Exercise

  Series A Warrants, issued in connection with an October 2025 private placement, expired on April 17, 2026.

• Significant Capital Raise

  Investors exercised warrants for 33,597,860 common shares at $1.40 per share and 4,883,464 pre-funded warrants at $1.399 per share.

• Gross Proceeds to Company

  The warrant exercises generated approximately $53.9 million in gross proceeds for Ovid Therapeutics.

• Share Issuance

  A total of 38,481,324 new shares (common and pre-funded) were issued as a result of the exercises.

auto_awesomeAnalysis

This filing reports a significant capital event for Ovid Therapeutics. The exercise of Series A Warrants has provided the company with a substantial cash infusion of $53.9 million, which significantly strengthens its balance sheet and provides crucial funding for its operations and pipeline development. While this event results in considerable dilution from the issuance of approximately 38.5 million new shares, the successful conversion of warrants into cash is a positive for the company's financial stability. Investors should view this as a necessary step to secure funding, with the dilution being a known consequence of the prior private placement.